Xeris Pharmaceuticals Reports Second Quarter 2020 Financial Results and Corporate Highlights
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/24/2026
- Wall Street ends lower on semiconductor selloff as AI spending concerns mount
- Alphabet added to Dow Jones Industrial Average, Verizon dropped
- Chip stocks plunge, but bargain-hunters limit scale of tech rout
- FedEx falls 4% as CY2026 profit forecast misses expectations despite Q4 beat
- Oil prices finish 1% lower as investors focus on Hormuz flows after peace talks
- Needham Starts NeoVolta (NEOV) at Buy
- NextEra to discuss paying about $76 per share for Dominion, Bloomberg News reports
- Wall Street ends lower on semiconductor selloff as AI spending concerns mount
- Campbell Soup (CPB) Declares $0.39 Quarterly Dividend; 7.7% Yield
- China, US, UAE police arrest 276 telecom fraud suspects in Dubai
Xeris Pharmaceuticals Inc. (XERS) Tops Q2 EPS by 10c, Revenues Beat
August 10, 2020 7:12 AM EDTXeris Pharmaceuticals Inc. (NASDAQ: XERS) reported Q2 EPS of ($0.63), $0.10 better than the analyst estimate of ($0.73). Revenue for the quarter came in at $1.99 million versus the consensus estimate of $1.86 million.
Our strong performance this quarter reflects Xeris dedication to the communities we serve, despite numerous pandemic-related... More
